Health Care Financing Administration publishes final rule providing for reimbursement of home use of epoetin in end-stage renal disease in Jan. 10 Federal Register. Final rule is essentially unchanged from Sept. 4, 1991 interim rule. HCFA notes that facilities generally pay about 10% less than the Medicare reimbursement rate of $11 per 1,000 units for EPO. Amgen "gave surveyed facilities end-of-year rebates ranging from 2% to 8% depending upon the volume of EPO used," HCFA says, concluding that reimbursement of EPO would be adequate to cover other supplies...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth